Sjögren's syndrome: dry eyes, dry mouth, and the GP role in diagnosis

Sjögren’s syndrome is a systemic autoimmune condition in which immune cells infiltrate and damage the body’s exocrine glands — primarily the lacrimal and salivary glands — causing persistent dryness of the eyes and mouth. Fatigue, joint pain, and parotid gland swelling are common accompaniments. More than two thirds of patients go five to ten years without a correct diagnosis, because dry eyes and dry mouth are attributed to ageing, antihistamines, or other common causes. The general practitioner is the first person in a position to interrupt that delay.

Understanding when to consider Sjögren’s syndrome, what initial workup to order, and how to share long-term care with rheumatology and ophthalmology is the focus of this article.

A. Core clinical — the AU general-practice framework

Who gets Sjögren’s syndrome?

Australian prevalence is approximately 0.5–1% of adults, with women affected nine to ten times more often than men. There is a bimodal peak: women in their twenties to thirties who often have secondary Sjögren’s syndrome alongside lupus or another connective tissue disorder, and women in their forties to sixties who more commonly have primary Sjögren’s syndrome in isolation. Onset is insidious; most patients experience symptoms for years before any investigation is ordered.

Primary Sjögren’s syndrome (pSS) occurs without an associated systemic connective tissue disease. Secondary Sjögren’s syndrome (sSS) occurs in the context of rheumatoid arthritis, systemic lupus erythematosus (SLE), systemic sclerosis, or mixed connective tissue disease — affecting up to 30% of patients with established rheumatoid arthritis. Management of sSS is largely determined by the underlying disease.

The cardinal features — sicca syndrome

Dry eyes (keratoconjunctivitis sicca): patients describe a gritty or sandy foreign-body sensation, burning, photophobia, and blurred vision that worsens through the day. Symptoms lasting more than three months and present most days of the week are the key threshold for investigation. By contrast, intermittent morning grittiness from incomplete lid closure or meibomian gland dysfunction is common and usually not Sjögren’s.

Dry mouth (xerostomia): difficulty chewing and swallowing dry food, needing water with every meal, altered taste, rampant cervical or smooth-surface dental caries despite regular brushing, oral candidiasis (often presenting as angular cheilitis), and a feeling that the mouth “sticks to itself.” Parotid gland swelling — often bilateral, episodic, and non-tender — is characteristic. Salivary flow may be visibly reduced: a clinical “mirror-stick test” (a mirror placed on the tongue sticks in a normal-flow mouth) is a quick bedside screen.

Fatigue: reported by up to 75% of patients and frequently the dominant complaint driving the GP visit. It is characterised as pervasive and not relieved by rest, distinct from the post-exertional fatigue of myalgic encephalomyelitis/chronic fatigue syndrome but often coexisting with fibromyalgia.

Systemic features to actively screen for:

• Arthralgia and arthritis — present in about half of patients; typically non-erosive, symmetric, involving the small joints of the hands.
• Raynaud’s phenomenon — in approximately 30%.
• Neuropathy — small-fibre or sensory neuropathy causing burning in the feet, mononeuritis multiplex; formal neurological assessment warranted.
• Pulmonary — dry cough, breathlessness from lymphocytic interstitial pneumonia or non-specific interstitial pneumonia; refer for spirometry and DLCO if respiratory symptoms present.
• Renal — distal renal tubular acidosis (low urine pH, hypokalaemia, nephrocalcinosis); check urinalysis and serum potassium.

Diagnosis — the ACR/EULAR 2016 criteria

Formal diagnosis uses the ACR/EULAR 2016 classification criteria (Shiboski Ann Rheum Dis 2017), which are point-scored:

Feature	Points
Anti-Ro/SSA antibodies positive	3
Minor lip salivary gland biopsy — focal score ≥1 per 4 mm²	3
Abnormal ocular staining score ≥5	1
Schirmer’s test ≤5 mm in 5 minutes	1
Unstimulated whole salivary flow ≤0.1 mL/minute	1

A total score ≥4 confirms primary Sjögren’s syndrome. The most important single finding for the GP is a positive anti-Ro/SSA antibody — present in approximately 60–70% of primary Sjögren’s syndrome cases, it alone contributes 3 points and triggers further specialist workup.

GP workup to initiate

RACGP and eTG Rheumatology recommend GPs initiate the following when Sjögren’s syndrome is suspected:

Blood tests: ANA; ENA panel including anti-Ro/SSA and anti-La/SSB; rheumatoid factor and anti-CCP (to exclude rheumatoid arthritis); anti-dsDNA if SLE features; FBC; ESR, CRP; UEC, eGFR; LFTs; TSH (thyroid disease is a common comorbidity); serum protein electrophoresis and free light chains (lymphoma surveillance baseline); HCV and HIV serology (both mimic Sjögren’s and are exclusion criteria); urinalysis.

Referrals: ophthalmologist or optometrist for Schirmer’s test, ocular staining with lissamine green and fluorescein, and tear break-up time; rheumatology for formal diagnosis, lip biopsy if indicated, and systemic management planning.

Imaging: parotid ultrasound (MBS item 55054) — heterogeneous parenchyma with hypoechoic foci is characteristic; increasingly used as a first-line investigation replacing scintigraphy.

Medications that worsen sicca and should be identified in the drug history: antihistamines, tricyclic antidepressants, anticholinergics, SSRIs (dry mouth in up to 30%), opioids, diuretics.

B. Management of sicca symptoms

Local measures form the foundation of management for the majority of patients whose disease is predominantly glandular.

Dry eye management

EULAR 2020 recommendations (Ramos-Casals ARD) support a step-care approach:

1. Preservative-free artificial tears — used liberally throughout the day; preservative-containing drops worsen corneal inflammation over time. Viscous formulations (carbomers, hyaluronic acid) are more durable. Night-time lubricating ointment helps with overnight dryness.
2. Lid hygiene and warm compresses — meibomian gland dysfunction frequently coexists and exacerbates aqueous deficiency; once or twice daily warm compresses + lid massage improve meibum flow.
3. Anti-inflammatory eye drops — ciclosporin 0.05% (Restasis) or lifitegrast 5% (Xiidra) for moderate-to-severe dry eye with corneal staining; prescribed by an ophthalmologist; PBS Authority Required for severe dry eye disease.
4. Punctal plugs — block the lacrimal drainage duct to retain tears; useful when aqueous deficiency is confirmed; placed by ophthalmologist.

Dry mouth management

• Frequent small sips of water.
• Sugar-free chewing gum or sugar-free hard sweets to stimulate residual salivary flow.
• Fluoride toothpaste twice daily; six-monthly dental review for caries risk.
• Oral candidiasis: nystatin pastilles or fluconazole per AMH.
• Salivary stimulants (sialagogues): pilocarpine 5 mg three times daily — Vivino Arch Intern Med 1999 demonstrated significant improvement in xerostomia and salivary flow in controlled trials; cholinergic side effects (sweating, flushing, urinary frequency) limit use in some patients; contraindicated in narrow-angle glaucoma, uncontrolled asthma, severe COPD.
• Alcohol-free mouth rinses and avoiding caffeine and alcohol, which worsen dryness.

Systemic treatment — hydroxychloroquine

Hydroxychloroquine (Plaquenil) is the most commonly prescribed disease-modifying agent in Sjögren’s syndrome. EULAR 2020 recommends it for patients with significant fatigue, arthralgia, or skin involvement. The JOQUER trial (Gottenberg JAMA 2014) did not demonstrate improvement in the primary endpoints of pain, dryness, or fatigue at 24 weeks compared with placebo; however, the trial was criticised for a short follow-up and high placebo response. Registry data and clinical experience broadly support its use.

Practical points for GPs prescribing hydroxychloroquine:

• Standard dose: 200–400 mg daily; maximum 5 mg/kg/day to limit retinopathy risk.
• PBS listing: hydroxychloroquine is listed for rheumatoid arthritis and SLE; prescribing for pSS is off-label but common and accepted practice in AU rheumatology.
• Baseline ophthalmology retinopathy screen, then annually from five years of use per RANZCO guidelines.
• Counsel that onset of effect is 3–6 months; a 6-month trial is needed before concluding inefficacy.

C. Lymphoma surveillance — the most important long-term GP task

Patients with primary Sjögren’s syndrome have an approximately 40-fold increased lifetime risk of B-cell non-Hodgkin lymphoma, predominantly mucosa-associated lymphoid tissue (MALT) lymphoma arising in the parotid gland. The absolute lifetime risk is approximately 5–10%. MALT lymphoma is typically slow-growing, but can transform to diffuse large B-cell lymphoma.

High-risk features for lymphoma:

• Persistent or asymmetric parotid gland enlargement.
• Palpable purpura (cutaneous vasculitis) — the strongest clinical predictor.
• Low complement levels (C4 in particular) — monoclonal band on protein electrophoresis.
• Cryoglobulinaemia.
• Peripheral lymphadenopathy.
• CD4 lymphopenia.

Surveillance approach per Theander ARD 2006 and EULAR 2020:

• Annual review with RACGP and rheumatology: examine parotid glands, cervical and axillary lymph nodes; ask about B symptoms (fever, night sweats, unintentional weight loss).
• Six-to-twelve-monthly parotid ultrasound in high-risk patients.
• Refer urgently for excisional or core biopsy of any persistent unilateral parotid mass, rapidly enlarging gland, or systemic B symptoms.

D. Australian operations

MBS items

Standard consultation items 23, 36, and 44 apply. The complexity of multi-system Sjögren’s syndrome often warrants Level D consultations. GP Management Plan and Team Care Arrangement items 965 and 967 (GPCCMP) support ongoing chronic disease management, allied health referrals, and hydroxychloroquine monitoring. ATSI Health Assessment item 715 applies where relevant. Referral item 105 for rheumatology, ophthalmology, or oral-maxillofacial surgery consultations. GP Mental Health Treatment Plan items 2715/2717 for co-existing depression or anxiety from chronic illness.

Parotid ultrasound

MBS item 55054 — salivary gland ultrasound — is GP-initiable and is replacing scintigraphy and sialography as the first-line gland assessment. A heterogeneous parotid parenchyma with hypoechoic foci, loss of normal lobular architecture, and absent or reduced Doppler signal is characteristic of Sjögren’s.

PBS

Hydroxychloroquine is listed under PBS general schedule for rheumatoid arthritis and SLE; prescribing for Sjögren’s syndrome is routine AU rheumatology practice. Ciclosporin 0.05% eye drops (Restasis) — Authority Required for severe dry eye. Artificial tear formulations are not PBS-subsidised but are widely available over the counter.

Referral pathways

• Rheumatology (within 4–8 weeks): confirmed or strongly suspected primary Sjögren’s syndrome, positive Ro/SSA antibody with sicca symptoms.
• Ophthalmology (within 4 weeks): moderate-to-severe dry eye not responding to OTC tears; corneal staining suspected.
• Oral medicine or oral-maxillofacial surgery: for lip biopsy if Ro/SSA is negative but clinical suspicion remains high.
• Haematology or oncology (urgent): persistent unilateral parotid mass; B symptoms; rapidly enlarging lymph node.
• Perinatal medicine: anti-Ro/SSA-positive women planning pregnancy or already pregnant.

E. Special populations

Pregnancy. The most important complication in Sjögren’s syndrome-associated pregnancies is neonatal lupus and congenital heart block (CHB) caused by transplacental transfer of anti-Ro/SSA antibodies. The risk of CHB in a first affected pregnancy is approximately 2%. Once complete CHB is established, it is irreversible and often requires a permanent pacemaker. RANZCOG and ACR recommendations are clear: all anti-Ro/SSA-positive pregnancies require referral to a foetal medicine service, continuation or commencement of hydroxychloroquine (which reduces recurrence risk), and weekly foetal echocardiography from 16 to 28 weeks. If there has been a prior affected pregnancy, the recurrence risk rises to approximately 17% and surveillance should be intensified. All anti-Ro/SSA-positive women of reproductive age should be counselled about this risk at diagnosis.

Older adults. Sicca symptoms are common in older adults from age-related gland atrophy, medication effects, and incomplete lid closure. Sjögren’s-specific dryness is distinguished by the combination of objective test abnormalities, positive autoantibodies, and systemic features. Medication review — antihistamines, anticholinergics, tricyclics, diuretics — should precede serological investigation in mild presentations.

Secondary Sjögren’s syndrome. In patients with established rheumatoid arthritis, SLE, or systemic sclerosis, Sjögren’s features are managed primarily within the treatment of the underlying disease. Hydroxychloroquine is often already prescribed. Methotrexate and other DMARDs used for RA or SLE can reduce systemic Sjögren’s activity. Rheumatology drives the overall plan.

Mental health. Chronic fatigue, pain, and disfiguring xerostomia create significant psychological burden. Rates of depression and anxiety are elevated compared with the general population. Screening with PHQ-9 and GAD-7 at each chronic-disease review is appropriate; access via GP Mental Health Treatment Plan (MBS items 2715/2717).

When to escalate

• Persistent unilateral or rapidly enlarging parotid mass — urgent haematology or oncology referral (same week).
• B symptoms (fever, night sweats, weight loss) in a known Sjögren’s patient — urgent review.
• Suspected congenital heart block in pregnancy — same-day obstetric and foetal medicine referral.
• New breathlessness or Velcro crackles — chest high-resolution CT and respiratory referral.
• Peripheral neuropathy — EMG/nerve conduction studies; neurology review.
• Severe hypokalaemia or low urinary pH — suspect distal renal tubular acidosis; nephrology review.
• Refractory sicca despite full local treatment — ophthalmology or oral medicine specialist escalation.
• Unexplained cytopenias or monoclonal band — haematology review.

What this article is and is not

This is general health information based on current Australian and international guidelines — RACGP, eTG Rheumatology, EULAR 2020, and ACR/EULAR 2016 criteria — written for patients who want to understand Sjögren’s syndrome and how their general practitioner approaches it. It is not personal medical advice and does not replace assessment by your own GP, rheumatologist, or ophthalmologist.

For Australian patient information: Arthritis Australia, HealthDirect — Sjögren syndrome.

For mental health support: Beyond Blue 1300 22 4636, Lifeline 13 11 14.

---

Sources cited

1. RACGP — Sjögren syndrome: a guide for general practice
2. Therapeutic Guidelines (eTG) — Rheumatology: Sjögren syndrome
3. Australian Rheumatology Association (ARA)
4. Australian Medicines Handbook (AMH)
5. PBS — hydroxychloroquine listing
6. Arthritis Australia — Sjögren syndrome
7. HealthDirect — Sjögren syndrome
8. EULAR 2020 recommendations — Ramos-Casals ARD
9. ACR/EULAR 2016 classification criteria — Shiboski Ann Rheum Dis 2017
10. RANZCOG — congenital heart block and anti-Ro/SSA
11. Theander — lymphoma risk in pSS (ARD 2006)
12. Gottenberg et al. — JOQUER trial (JAMA 2014)
13. Vivino — pilocarpine for xerostomia (Arch Intern Med 1999)